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Correlation, Confounding, and Confusion*Sunil V. Rao, MD, Amit N. Vora, MD, MPHF ew therapies in medicine are as controversialor have as much conﬂicting data as bloodtransfusions and their role in managing criti-
cally ill patients, especially those with acute myocar-
dial infarction (MI). Despite almost 200 years of
research, advancements in transfusion medicine,
and an estimated 13.8 million units of red blood cells
transfused annually in the United States (1), current
guidelines for transfusing red blood cells among hos-
pitalized patients are ill-deﬁned. The most recently
published American College of Cardiology/American
Heart Association guidelines for managing patients
with non–ST-segment elevation acute coronary syn-
dromes (ACS) (2) give a class III (no beneﬁt) recom-
mendation for routine blood transfusion in MI
patients with a hemoglobin value >8 g/dl. The Amer-
ican Association of Blood Banks, in contrast, offers no
recommendation either for or against transfusion in
this population (3). However, these recommendations
are based almost exclusively on observational data.SEE PAGE 2510In this issue of the Journal, Ding et al. (4) provide
additional insight into differential transfusion
thresholds in the presence of cardiac disease. In
an observational analysis of >250,000 patients
admitted to 108 Veterans Affairs hospital intensive
care units (ICUs), they report an association between
transfusion and lower adjusted mortality at a baseline
hemoglobin level <7.7 g/dl among all patients.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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Vora was funded by NIH T-32 training grant T32 HL069749 and L30
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ships relevant to the contents of this paper to disclose.This threshold was higher among patients with co-
morbid cardiac conditions (transfusion threshold of
8.7 g/dl) and approximately 10 g/dl among patients
for whom the primary ICU diagnosis was acute MI.
This analysis adds to a remarkably consistent body
of knowledge, especially in the observational litera-
ture, that describes the hazard of blood transfusion in
critically ill patients (5) and a higher transfusion
threshold among patients presenting with acute MI.
Despite the available data, it is difﬁcult to offer clear
guidance regarding the appropriate transfusion
threshold among patients with ischemic heart disease
in the absence of a prospective, well-powered ran-
domized trial. Treatment selection bias remains the
largest limitation for even large-scale observational
studies, and currently used methods to address these
concerns have proved incomplete.
Therefore, while awaiting a deﬁnitive randomized
trial, the challenge in designing future observational
studies may be to use robust methodologies to over-
come the shortcomings of traditional observational
research. One such technique, propensity matching,
is used frequently to account for comparator group
differences. However, a recent study by Salisbury
et al. (6) that evaluated the association between
transfusion and mortality among acute MI patients
demonstrated that >90% of the 34,937 patients in
their study had nonoverlapping propensity scores,
making them unsuitable for direct comparison.
In the current analysis, the investigators used a
well-described, although infrequently used tech-
nique, called principal component analysis (PCA),
which creates a set of artiﬁcial variables (principal
components) based on correlations from amuch larger
dataset. Ostensibly, these principal components can
be used more manageably in subsequent analyses.
PCA is most helpful in situations that involve highly
correlated variables and can potentially deal with
the issue of collinearity. This technique may prove
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those that use large electronic health record data-
bases, by reducing a large set of comorbid diagnoses
into a small number of variables (the principal com-
ponents) to study interactions between diagnoses
and treatment or to adjust for multidimensional
comorbidities that the treatment effect may be con-
founding. However, it is useful only in a very limited
context; speciﬁcally, one in which the variables being
composited are not themselves the true confounders,
but instead are highly correlated versions of the true
confounder. The primary statistical concern with PCA
is that it may unnecessarily complicate an analysis
by creating nonsensical components (or new con-
founders) that no longer adequately adjust for the
original measured confounders. As such, PCA’s utility
in an observational analysis comparing therapies
remains unclear.
Instrumental variables offer another technique
that may address confounding in determining the
association between transfusion and outcome (7). An
instrumental variable is associated with the treat-
ment but not the outcome, and instrumental variable
analysis attempts to “simulate” randomization in the
context of an observational dataset by overcoming
the effect of unmeasured confounding. An example
of an instrumental variable analysis is a study by
Federspiel et al. (8), which evaluated the association
between drug-eluting stents (DES) and mortality and
revascularization among 62,309 Medicare beneﬁ-
ciaries treated between May 2003 and February 2004.
In the randomized trials that compared drug-eluting
and bare-metal stents, DES reduced the rate of
repeat revascularization, but they did not affect
mortality (9), even in the setting of acute MI (10). A
large observational analysis of a statewide registry
used propensity matching and demonstrated an as-
sociation between DES and reduced mortality among
patients with acute MI (11), which was a ﬁnding
that contrasted with the randomized trials and was
likely subject to residual confounding. The analysis
by Federspiel et al. (8) used multivariate adjustment,
propensity matching, and instrumental variables.
A “month of percutaneous coronary intervention”
(PCI) was used as the instrument because it affected
whether the patient received a DES (patients treated
later were more likely to receive DES due to rapid DES
adoption), but it did not affect the outcomes. In the
multivariate and propensity analyses, DES use was
associated with reduced mortality; in the instru-
mental variable analysis, DES use was associated with
reduced repeat revascularization, but had no effect
on mortality, directly replicating the results of
the randomized trials. Instrumental variables mayprovide several advantages to conventional methods
of dealing with confounding, but the challenge is
picking the right instrument.
Ultimately, randomized trials present the only
deﬁnitive way to address the role of a therapy. In the
context of blood transfusion, the stage has been long
set for an adequately powered trial comparing trans-
fusion strategies in ACS patients. To date, there have
been only 2 small, randomized pilot studies (total
n ¼ 155) (12,13), but they yielded conﬂicting results.
Recently published randomized trials in other clinical
situations continue to strengthen the rationale for a
decisive study. Steiner et al. (14) cast doubt on the
so-called “storage lesion” in transfusion, ﬁnding no
substantial difference in outcomes between trans-
fused blood stored for <10 days than blood stored
for $21 days. Another recent study highlighted
the role of transfusion strategy among patients
who underwent cardiac surgery; although there was
no observed difference in the primary composite
outcome between a restrictive and liberal strategy,
there was an unexpected signal for increased mor-
tality with the restrictive strategy (15).
Despite publication of the TRICC (Transfusion in
Critical Care) trial (16) >15 years ago and repeated
calls for a deﬁnitive randomized trial to address the
optimal transfusion strategy for patients with acute
MI, the fact that a trial has not been completed speaks
to the challenges associated with designing and
implementing such a trial, including logistics, gener-
alizability, and cost. However, recent developments
in clinical trial design may mitigate some of these
issues. One strategy is the registry-based randomized
trial, which was used in the TASTE (Thrombus
Aspiration in ST-Elevation Myocardial Infarction in
Scandinavia) (17) and SAFE-PCI (Study of Access Site
for Enhancement of PCI for Women) (18) trials. The
registry-based trial potentially reduces the cost and
complexity associated with data management by
embedding randomization within a large ongoing
registry, such as the National Cardiovascular Data
Registry’s CathPCI or ACTION (Acute Coronary Treat-
ment and Intervention Outcomes Network) Registry.
These registries routinely collect some data elements
that are relevant for a transfusion trial (baseline he-
moglobin, comorbidities, cardiac catheterization, PCI,
coronary artery bypass graft surgery) and in-hospital
outcomes. Leveraging this data collection reduces
site-level workload and costs. Another strategy,
used by PCORNet (Patient-Centered Clinical Research
Network) to evaluate optimal aspirin dosing for sec-
ondary prevention (19), would be to embed the trial
within traditional care pathways and use electronic
health records to capture events. Because of the site
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patients (6,20), a cluster-based randomized trial may
also be feasible. This technique previously has been
used effectively to generate informative data in
the cardiovascular (21) and noncardiovascular (22,23)
arenas. All of these strategies represent novel ways to
perform rigorous, randomized trials for a fraction of
the traditional trial cost and complexity by leveraging
either ongoing data collection or patterns of care in
clinical practice.
Until observational studies effectively deal with
confounding, the correlations they ﬁnd will only add
to the confusion at the bedside. Instead, the way for-
ward may be a combination of approaches: usingnovel statistical techniques in observational datasets
to glean additional insights while incorporating
recent advances in clinical trial methodology to
design a simple, pragmatic trial to determine the
optimal transfusion strategy among acute MI patients.
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